Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Fixed-Sequence, Open-Label, Switch-Over Study of the Safety and Tolerability of HPN-100 Compared to Sodium Phenylbutyrate in Children 6-17 Years of Age With Urea Cycle Disorders, With a Long-Term Safety Extension

NCT00947544 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00947544
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00947544 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Fixed-Sequence, Open-Label, Switch-Over Study of the Safety and Tolerability of HPN-100 Compared to Sodium Phenylbutyrate in Children 6-17 Years of Age With Urea Cycle Disorders, With a Long-Term Safety Extension
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2010
Completion date
August 31, 2011
Enrollment
17 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

urea cycle disorders